Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study.

Plain-language guide to PMID 31049877 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Key Facts

PMID: 31049877
Journal: Aging clinical and experimental research
Year: 2019
Study type: Randomized Controlled Trial
Authors: Liberman K et al. (15 authors)
DOI: 10.1007/s40520-019-01208-4

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

To investigate whether 13 weeks of nutritional supplementation of VitD and leucine-enriched whey protein affected CLIP in subjects enrolled in the PROVIDE-study, as a secondary analysis.

Why It Was Studied

Protein and Vitamin (Vit)D have immune-modulatory potential, but evidence for effects of nutritional supplementation on CLIP is limited.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Data-analysis included repeated measures analysis of covariance (corrected for dietary VitD intake) and linear regression.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Interleukin 1 Receptor Antagonist Protein, Interleukin-6, Leucine, Mobility Limitation, Muscle, Skeletal and Sarcopenia.

The authors tagged it with the keywords Aged, Cytokines, Vitamin D and Whey proteins.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Aging clinical and experimental research), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.

Our Notes on the Compounds

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.